SavedAdd your journal

Journals / Acta Odontologica Turcica / 2013 / Cilt: 30 - Sayı: 1

Bisphosphonates and osteonecrosis of the jaws

Bifosfonatlar ve çenelerde görülen osteonekroz

Arzu Zeynep YILDIRIM BİÇER
Pages
35–8
Publication Date
2013-03-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Dentists should be cautious in the treatment of patients using bisphosphonates.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Bisphosphonates are widely used for treatment of many bone metabolism related disease.
📊
Key Findings & Data:Intravenous administration of high doses of bisphosphonates for the management of benign conditions occasionally lead to development of osteonecrosis of the jaws.
💡
Conclusion & Impact:Dentists should be cautious in the treatment of patients using bisphosphonates.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Bifosfonat · Çene · Osteonekroz

Abstract

Bisphosphonates are widely used for treatment of many bone metabolism related disease. Intravenous administration of high doses of bisphosphonates for the management of benign conditions occasionally lead to development of osteonecrosis of the jaws. In many cases lesions appear spontaneously or following an infection or a tooth extraction. Dentists should be cautious in the treatment of patients using bisphosphonates.

Özet

Bifosfonatlar günümüzde kemik metabolizması ile ilgili pek çok hastalığın tedavisinde yaygın olarak kullanılmaktadır. Bifosfonatların yüksek dozda intravenöz uygulamaları nedeni ile ilaca bağlı bir yan etki olarak çenelerde osteonekroz oluşabilmektedir. Lezyonlar kendiliğinden oluşabildiği gibi bir enfeksiyon ve diş çekimi genellikle olayı hızlandırmaktadır. Bu nedenle diş hekimleri bifosfonat kullanan hastaların tedavisinde dikkatli olmalıdırlar.

🔖

Cite This Article

BİÇER, A. Z. Y. (2013). Bisphosphonates and osteonecrosis of the jaws. Acta Odontologica Turcica, Cilt: 30 - Sayı: 1, 35–8. https://ajindex.com/articles/265500

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90:1897-99.
  2. Ergün S, Güneri P, Koca H. Çene kemiklerinin yeni tehlikesi: bifosfonatlar. Cumhuriyet Üniversitesi Diş Hekimliği Fakültesi Derg 2008;11(2):140-5.
  3. Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice Clin Interv Aging 2008;3:279-97.
  4. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Inter Med 2008;148:197-213.
  5. Nase JB, Suzuki JB. Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 2006;137:1115-9. Reilly MM. Osteonecrosis of the jaw in a patient receiving bisphosphonate therapy. Oncol Nurs Forum 2007;34:301-5.
  6. Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, et al. The effects of suppressed bone remodelling by bisphosponates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005;23:36-42.
  7. Akarslan ZZ, Kahraman SA. Kemik metastazı yapmış prostat kanseri tedavisinde kullanılan bifosfonata bağlı olarak çene kemiklerinde gelişen osteonekroz: vaka raporu ve literatür derlemesi. Atatürk Üniv Diş Hek Fak Derg 2008;18:105-10. Fleish H. Bisphosphonates: mechanism of action. Endocr Rev 1998;19:80-100. Sarıdoğan M. Postmenopozal osteoporoz tedavisi: bifosfonatlar. Akad Geriatri 2010;183-8.
  8. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
  9. Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract Suppl 1999;101:18-26.
  10. Markiewicz MR, Margarone JE 3rd, Campbell JH, Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 2005;136:1669-74.
  11. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, et al. Zoledronic acid-related antiangiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005;25:144-51.
  12. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphophonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.
  13. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: